← Back to Search

Topical Corticosteroid and Retinoid Combination

Duobrii for Scalp Psoriasis

Phase 4
Waitlist Available
Led By Zoe D Draelos, MD
Research Sponsored by Dermatology Consulting Services, PLLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* 1. Males or non-pregnant females 18+ years of age. 2. Plaque type moderate to severe scalp psoriasis suitable for topical treatment.
3. Subjects must be in general good health as determined from a medical history.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
No Placebo-Only Group
Drug Has Already Been Approved
Pivotal Trial

Summary

This trial tests a special lotion for people with serious scalp psoriasis. The lotion combines two medications to slow skin cell growth and reduce redness and itching. Patients will use it daily for a few months to see if it improves their condition. The lotion being tested combines calcipotriol and betamethasone dipropionate, which have been shown to be effective and well-tolerated in previous studies for treating scalp psoriasis.

Eligible Conditions
  • Psoriasis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Hair Growth
Scalp Itch

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Active ArmExperimental Treatment1 Intervention
0.045% Tazarotene/0.01% Habetasol Lotion apply once daily at bedtime to the scalp afflicted with psoriasis
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
0.045% Tazarotene/0.01% Halobetasol Lotion
2023
Completed Phase 4
~20

Find a Location

Who is running the clinical trial?

Ortho DermatologicsIndustry Sponsor
4 Previous Clinical Trials
1,201 Total Patients Enrolled
1 Trials studying Psoriasis
25 Patients Enrolled for Psoriasis
Dermatology Consulting Services, PLLCLead Sponsor
3 Previous Clinical Trials
100 Total Patients Enrolled
1 Trials studying Psoriasis
10 Patients Enrolled for Psoriasis
Zoe D Draelos, MDPrincipal InvestigatorDermatology Consulting Services, PLLC
6 Previous Clinical Trials
325 Total Patients Enrolled
1 Trials studying Psoriasis
46 Patients Enrolled for Psoriasis

Media Library

0.045% Tazarotene/0.01% Halobetasol Lotion (Topical Corticosteroid and Retinoid Combination) Clinical Trial Eligibility Overview. Trial Name: NCT05872256 — Phase 4
Psoriasis Research Study Groups: Active Arm
Psoriasis Clinical Trial 2023: 0.045% Tazarotene/0.01% Halobetasol Lotion Highlights & Side Effects. Trial Name: NCT05872256 — Phase 4
0.045% Tazarotene/0.01% Halobetasol Lotion (Topical Corticosteroid and Retinoid Combination) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05872256 — Phase 4
~8 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top